Agios Sells Cancer Portfolio To Servier To Focus On Genetic Diseases
$2bn Deal With $1.8bn Up Front For Idhifa Rights, Tibsovo And More
Executive Summary
Agios’ cellular metabolism expertise first delivered cancer drugs but sees greater opportunity in genetically defined diseases. CEO Jackie Fouse talked to Scrip about the business strategy.
You may also be interested in...
Agios’ Mitapivat Shows Improvement In Regularly Transfused PKD Patients
While representing a smaller population, the ACTIVATE-T trial targeted patients seen as having greater unmet need.
J.P. Morgan Day 3: Preparing For The Future, Whatever That Holds
Daily round-up from the virtual J.P. Morgan Healthcare Conference: Teva promises growth is coming; Relay joins Roche in the KRAS race; UCB embraces the digital age; Agios and Ionis prepare for commercial battles.
J.P. Morgan Day 3: Preparing For The Future, Whatever That Holds
Daily round-up from the virtual J.P. Morgan Healthcare Conference: Teva promises growth is coming; Relay joins Roche in the KRAS race; UCB embraces the digital age; Agios and Ionis prepare for commercial battles.
Need a specific report? 1000+ reports available
Buy Reports